203 related articles for article (PubMed ID: 38115063)
1. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
Zhang M; Wang J; Guo Y; Yue H; Zhang L
J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
[TBL] [Abstract][Full Text] [Related]
2. Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy.
Zhang M; Yue H; Huang X; Wang J; Li Z; Deng X
ACS Appl Mater Interfaces; 2022 Nov; 14(43):48502-48514. PubMed ID: 36261925
[TBL] [Abstract][Full Text] [Related]
3. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
[TBL] [Abstract][Full Text] [Related]
4. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin.
Zhu J; Lin S; Zou X; Chen X; Liu Y; Yang X; Gao J; Zhu H
Mol Biol Rep; 2023 Aug; 50(8):6457-6468. PubMed ID: 37326754
[TBL] [Abstract][Full Text] [Related]
6. Golgi phosphoprotein 3 promotes ovarian cancer progression and is associated with cisplatin resistance.
Liu T; Jin ZW; Li Y; Zhang G; Yang XY; Xu XM; Ma YC
J Cancer Res Ther; 2022 Apr; 18(2):488-495. PubMed ID: 35645119
[TBL] [Abstract][Full Text] [Related]
7. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
Ma J; Liu L; Ling Y; Zheng J
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
[TBL] [Abstract][Full Text] [Related]
8. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
Yang H; Li H; Lu S; Shan S; Guo Y
Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
[TBL] [Abstract][Full Text] [Related]
9. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
10. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
[TBL] [Abstract][Full Text] [Related]
12. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
Yin S; Mai Z; Liu C; Xu L; Xia C
Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
[TBL] [Abstract][Full Text] [Related]
13. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.
Zhu H; Diao S; Lim V; Hu L; Hu J
Acta Biochim Biophys Sin (Shanghai); 2019 May; 51(5):509-516. PubMed ID: 30939187
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
[TBL] [Abstract][Full Text] [Related]
15. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.
Wang X; Jiang L; Liu Q
J Transl Med; 2022 Jun; 20(1):258. PubMed ID: 35672774
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
[TBL] [Abstract][Full Text] [Related]
17. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer.
Huang W; Huang H; Xiao Y; Wang L; Zhang T; Fang X; Xia X
Cell Cycle; 2022 Apr; 21(8):780-791. PubMed ID: 35130130
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
19. REG3A promotes proliferation and DDP resistance of ovarian cancer cells by activating the PI3K/Akt signaling pathway.
Jiang L; Liu Y; Liu M; Zheng Y; Chen L; Shan F; Ji J; Cao Y; Kai H; Kang X
Environ Toxicol; 2024 Jan; 39(1):85-96. PubMed ID: 37665173
[TBL] [Abstract][Full Text] [Related]
20. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
